<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nifurtimox: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nifurtimox: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nifurtimox: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="126390" href="/d/html/126390.html" rel="external">see "Nifurtimox: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="128484" href="/d/html/128484.html" rel="external">see "Nifurtimox: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54008896"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lampit</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53833053"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiprotozoal</li></ul></div>
<div class="block doa drugH1Div" id="F53833070"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30e59abe-a2ad-490f-9035-73a0e0f3bbe5">Chagas disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chagas disease (<i>T. cruzi</i> infection; American trypanosomiasis) (alternative agent) (off-label use):</b>
<b>Oral:</b> 8 to 10 mg/kg/day in 3 to 4 divided doses for 90 days (Bern 2007; CDC 2019a; HHS [OI adult 2020]; Kappagoda 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ce29fc0-3207-40b3-8865-d955f73675dc">West African trypanosomiasis, with confirmed or suspected CNS involvement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>West African trypanosomiasis (<i>T. brucei gambiense</i> infection; sleeping sickness), with confirmed or suspected CNS involvement (off-label use): Oral:</b> 15 mg/kg/day in 3 divided doses for 10 days, in combination with eflornithine (CDC 2019b; Kappagoda 2011; Priotto 2009; WHO 2019).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> If a dose is missed, take the next dose as soon as possible; if it is ≤3 hours until the next scheduled dose, skip the missed dose and continue treatment as scheduled. Do not take a double dose to make up for a missed dose.</p></div>
<div class="block dora drugH1Div" id="F54770808"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Nifurtimox concentrations may be increased in patients with end-stage renal disease on hemodialysis; use with caution.</p></div>
<div class="block doha drugH1Div" id="F54770809"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F53833071"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F54475360"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="128484" href="/d/html/128484.html" rel="external">see "Nifurtimox: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5f84499-cbae-420f-be2a-d553aac0cc6c">American trypanosomiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>American trypanosomiasis</b>
<b> (Chagas disease; <i>Trypanosoma cruzi</i> infection): Note: </b>Dose should be adjusted if body weight changes during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i> (CDC 2021a; <i>Red Book</i> [AAP 2021]; manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight 2.5 to &lt;41 kg: Oral: 10 to 20 mg/kg/<b>day</b> in 3 divided doses for 60 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥41 kg: Oral: 8 to 10 mg/kg/<b>day</b> in 3 divided doses for 60 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-band (fixed) dosing</i> (manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;18 years: <b>Note:</b> Treat for 60 days.</p>
<p style="text-indent:-2em;margin-left:8em;">2.5 to 4.5 kg: Oral: 15 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;4.5 to &lt;9 kg: Oral: 30 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">9 to &lt;13 kg: Oral: 45 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">13 to &lt;18 kg: Oral: 60 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">18 to &lt;22 kg: Oral: 75 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">22 to &lt;27 kg: Oral: 90 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">27 to &lt;35 kg: Oral: 120 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">35 to &lt;41 kg: Oral: 180 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">41 to &lt;51 kg: Oral: 120 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">51 to &lt;71 kg: Oral: 180 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">71 to &lt;91 kg: Oral: 240 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥91 kg: Oral: 300 mg 3 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7cb9ca3-15fa-4c1a-a87d-0d41c6fa2d60">African trypanosomiasis, second-stage disease, caused by <i>Trypanosoma brucei gambiense</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>African trypanosomiasis (sleeping sickness), second-stage disease (with CNS involvement), caused by <i>Trypanosoma brucei gambiense</i>: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 15 mg/kg/<b>day</b> in 3 divided doses for 10 days in combination with IV eflornithine for 7 days (NECT regimen) (CDC 2021b; <i>Red Book</i> [AAP 2021]; WHO 2019).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F54475364"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Nifurtimox concentrations may be increased in patients with end-stage renal disease on hemodialysis; use with caution and monitor closely. Some experts would avoid use in patients with severe renal dysfunction (Bern 2007; Kappagoda 2011).</p></div>
<div class="block dohp drugH1Div" id="F54475365"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); some experts would avoid use in patients with severe hepatic dysfunction (Bern 2007; Kappagoda 2011).</p></div>
<div class="block adr drugH1Div" id="F53791836"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (13%), decreased appetite (11%), vomiting (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6%), urticaria (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (5%), nausea (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3%), eosinophilia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, drowsiness, fatigue, irritability, paresthesia, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia, myalgia, tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, amnesia, apathy, myasthenia, polyneuropathy, psychotic symptoms, sleep disorder</p></div>
<div class="block coi drugH1Div" id="F54760669"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to nifurtimox or any component of the formulation; alcohol consumption during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F53833060"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause muscle weakness or tremors, which may impair physical abilities; patients must be cautioned about performing tasks such as operating machinery or driving if weakness or tremors occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Loss of appetite and nausea/vomiting leading to weight loss have been reported. Monitor body weight every 2 weeks during treatment and adjust dosage based on weight as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reaction: Hypersensitivity reactions, sometimes accompanied by angioedema (including laryngeal or facial edema), dyspnea, hypotension, pruritus, rash, or other severe skin reactions, have been reported. The hypersensitivity may be due to nifurtimox or an immune response caused by Chagas disease during treatment. Discontinue use at the first sign of serious hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral neuropathy: Use has been associated with peripheral neuropathy; monitor for signs and symptoms during therapy (Crespillo-Andujar 2018; Forsyth 2016; Kappagoda 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution and close monitoring in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurological conditions: Use with caution and close monitoring in patients with a history of brain injury or seizures; worsening of the condition may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria; nitrofuran derivatives may precipitate acute attacks of porphyria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disease: Use with caution and close monitoring in patients with a history of psychiatric disease or serious behavioral alterations; worsening of the condition may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution and close monitoring in patients with end-stage renal disease requiring hemodialysis (serum concentrations are increased).</p></div>
<div class="block foc drugH1Div" id="F54008897"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lampit: 30 mg, 120 mg [contains corn starch]</p></div>
<div class="block geq drugH1Div" id="F54844070"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54868169"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lampit Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $3.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $3.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F53833051"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Nifurtimox is only available for the treatment of African trypanosomiasis (in combination with eflornithine) with an individual IND from the FDA. Additional IND information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Ftypes-applications%2Finvestigational-new-drug-ind-application&amp;token=jYUibQypl5xxvTDDEZHghwpw2PXR3Q0sczOWfM2QS%2FBONgkg9oWmv3urSr4gHDUbwZ8jtKQEhUHYwxkvitg2XIzvXzsn98Bb9dNnsyFdFng%3D&amp;TOPIC_ID=126252" target="_blank">https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application</a>.</p></div>
<div class="block adm drugH1Div" id="F53833072"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food. Tablets are functionally scored and may be split at the scored lines by hand; do <b>not</b> break mechanically with a tablet splitting device. In patients unable to swallow whole or half tablets, tablet may be dispersed in water. Place ~2.5 mL of water in a spoon and place the prescribed dose into the water. Allow the tablet(s) to disintegrate (usually &lt;30 seconds) until a slurry is formed. Administer the slurry immediately with food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>West African trypanosomiasis: </b>If vomiting occurs within 30 minutes of dose, repeat the same dose. If vomiting occurs within 30 to 60 minutes of dose, a half dose should be given. If vomiting occurs &gt;1 hour after dose, no additional dose is necessary. If nausea or vomiting persists, consider administering domperidone or metoclopramide before subsequent doses. If treatment is interrupted, the missing doses should be added at the end of treatment for a total of 30 doses of nifurtimox (WHO 2019).</p></div>
<div class="block admp drugH1Div" id="F54475367"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food. Tablets are functionally scored and may be split at the scored lines by hand; do <b>not</b> break mechanically with a tablet splitting device. In patients unable to swallow whole or half tablets, tablet may be dispersed in water. Place ~2.5 mL of water in a spoon and place the prescribed dose into the water. Allow the tablet(s) to disintegrate (usually &lt;30 seconds) until a slurry is formed. Administer the slurry immediately with food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>African trypanosomiasis (sleeping sickness; <i>T. brucei gambiense </i>infection):</b> If vomiting occurs within 30 minutes of dose, repeat the same dose. If vomiting occurs within 30 to 60 minutes of dose, a half dose should be given. If vomiting occurs &gt;1 hour after dose, no additional dose is necessary. If nausea or vomiting persists, consider administering domperidone (not available in the United States) or metoclopramide before subsequent doses (WHO 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>American trypanosomiasis (Chagas disease; <i>T. cruzi</i> infection):</b> If a dose is missed, administer as soon as possible; if it is ≤3 hours until the next scheduled dose, skip the missed dose and continue treatment as scheduled. Do not take a double dose to make up for a missed dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>African trypanosomiasis (sleeping sickness; <i>T. brucei gambiense </i>infection):</b> If treatment is interrupted, the missing doses should be added at the end of treatment for a total of 30 doses of nifurtimox (WHO 2019).</p></div>
<div class="block hazard drugH1Div" id="F54761103"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Nifurtimox may cause teratogenicity, reproductive toxicity, and genotoxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F53833055"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;">
<b>Chagas disease (<i>Trypanosoma cruzi</i> infection; American trypanosomiasis): </b>Treatment of Chagas disease in pediatric patients &lt;18 years of age and weighing ≥2.5 kg.</p></div>
<div class="block off-label drugH1Div" id="F53833056"><span class="drugH1">Use: Off-Label: Adult</span><p>West African trypanosomiasis (Trypanosoma brucei gambiense infection; sleeping sickness), with confirmed or suspected CNS involvement</p></div>
<div class="block mst drugH1Div" id="F53833049"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nifurtimox may be confused with nifuroxazide, nitrofurantoin, nitazoxanide.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53808795"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53808792"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nifurtimox.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F54761102"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases C<sub>max</sub>, AUC, and T<sub>max</sub>. Management: Administer with food.</p></div>
<div class="block rep_considerations drugH1Div" id="F53833058"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use; pregnancy testing is required prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 6 months after the last nifurtimox dose. Patients with partners who could become pregnant should use condoms during therapy and for 3 months after the last nifurtimox dose.</p></div>
<div class="block pri drugH1Div" id="F53833057"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to nifurtimox may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data related to the use of nifurtimox in pregnancy are limited (Kuemmerle 2022; Schmid 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Other agents may be preferred for the treatment of West African trypanosomiasis in pregnant patients when therapy cannot be postponed until after delivery. Nifurtimox should not be used during pregnancy unless treatment is considered life-saving for the mother (WHO 2019). Treatment of Chagas disease in pregnancy does not prevent transmission to the newborn; maternal treatment with nifurtimox is considered contraindicated by some guidelines and use should be postponed until after delivery (Carlier 2019; Meymandi 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to nifurtimox is ongoing. Health care providers are encouraged to enroll patients who become pregnant within 6 months of the last dose or who are exposed to nifurtimox during pregnancy in the pregnancy safety study (1-888-842-2937).</p></div>
<div class="block brc drugH1Div" id="F53833059"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Nifurtimox is present in breast milk (Moroni 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of nifurtimox in breast milk are available from a study of 10 lactating patients, 1 to 11 months postpartum, treated for Chagas disease. Patients were administered nifurtimox 8 to 12 mg/kg/day for 30 days and breast milk was sampled after ~3 and ~10 days of treatment. The highest breast milk concentration was 9.5 mg/L. Using the highest breast milk concentration from one patient, the authors of the study calculated the relative infant dose (RID) of nifurtimox to be 14.54%, based on the weight-adjusted maternal dose of 9.8 mg/kg/day, providing an estimated dose to the breastfed infant of 1.42 mg/kg/day. Using data from all 10 patients, the median concentration of nifurtimox in breast milk was 2.15 mg/L, providing a RID of 6.7%. Adverse events were not observed in the breastfed infants. Two infants required treatment for congenital Chagas disease (Moroni 2019). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the use of nifurtimox for the treatment of West African trypanosomiasis in breastfeeding patients are limited (Kuemmerle 2022; Schmid 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. However, breastfeeding may continue when nifurtimox is used for the treatment of West African trypanosomiasis in lactating patients (WHO 2019). Infants exposed to nifurtimox via breast milk should be monitored for adverse events, including decreased appetite, irritability, pyrexia, rash, or vomiting.</p></div>
<div class="block dic drugH1Div" id="F54770810"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food. Avoid alcohol.</p></div>
<div class="block mop drugH1Div" id="F53833074"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pregnancy test prior to use in patients who could become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional monitoring is dependent on the anticipated length of treatment:</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment course ≤10 days: Renal function, hepatic function, and CBC at baseline and during treatment if clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment course &gt;10 days: Renal function, hepatic function, and CBC at baseline, at least once during treatment (some experts recommend every 4 to 6 weeks [Bern 2020]), and at therapy completion; periodically screen for peripheral neuropathy during treatment (Kappagoda 2011; Olivera 2017). Monitor body weight every 2 weeks during therapy.</p></div>
<div class="block pha drugH1Div" id="F53833063"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Not well described. It has been suggested that nifurtimox is metabolized/activated by type I (oxygen insensitive) and type II (oxygen sensitive) nitroreductases, leading to production of toxic intermediate metabolites and/or reactive oxygen species that induce DNA damage and cell death of both intracellular and extracellular forms of <i>T. cruzi</i>.</p></div>
<div class="block phk drugH1Div" id="F53833064"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapidly absorbed (WHO 1995). Administration with a high-fat meal (800 to 1,000 calories; ~60% fat) increased C<sub>max</sub> and AUC by 68% and 71%, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 42%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively metabolized in the liver, where nitroreduction occurs through CYP450 reductase (Bern 2007; WHO 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2.4 to 3.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 4 hours (range: 2 to 8 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: ~27% (fasted conditions) to 44% (fed conditions), primarily as metabolites.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F53909082"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Furtimox</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lampit</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lampit</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bern C. Chagas disease: Antitrypanosomal drug therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 19, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18000201">
<a name="18000201"></a>Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. <i>JAMA</i>. 2007;298(18):2171-2181. doi: 10.1001/jama.298.18.2171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/18000201/pubmed" id="18000201" target="_blank">18000201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31647811">
<a name="31647811"></a>Carlier Y, Altcheh J, Angheben A, et al. Congenital Chagas disease: updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women. <i>PLoS Negl Trop Dis</i>. 2019;13(10):e0007694. doi: 10.1371/journal.pntd.0007694.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/31647811/pubmed" id="31647811" target="_blank">31647811</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Parasites - American trypanosomiasis (also known as Chagas disease): Antiparasitic treatment. <a href="https://www.cdc.gov/parasites/chagas/health_professionals/tx.html" target="_blank">https://www.cdc.gov/parasites/chagas/health_professionals/tx.html</a>. Updated October 9, 2019. Accessed November 6, 2019a.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Parasites - American trypanosomiasis (also known as Chagas disease): Antiparasitic treatment. <a href="https://www.cdc.gov/parasites/chagas/health_professionals/tx.html" target="_blank">https://www.cdc.gov/parasites/chagas/health_professionals/tx.html</a>. Updated June 14, 2021a. Accessed February 21, 2022.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Parasites - African trypanosomiasis (also known as sleeping sickness): Resources for health professionals. <a href="https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html</a>. Updated June 6, 2019b. Accessed October 25, 2019b.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Parasites - African trypanosomiasis (also known as sleeping sickness): Resources for health professionals. <a href="https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html</a>. Updated July 28, 2021b. Accessed February 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29906591">
<a name="29906591"></a>Crespillo-Andujar C, Chamorro-Tojeiro S, Norman F, Monge-Maillo B, López-Vélez R, Pérez-Molina JA. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail. <i>Clin Microbiol Infect</i>. 2018;24(12):1344.e1-1344.e4. doi: 10.1016/j.cmi.2018.06.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/29906591/pubmed" id="29906591" target="_blank">29906591</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Drugs for parasitic infections. <i>Med Lett Drugs Ther.</i> 2013;11(suppl):e1-e31.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432838">
<a name="27432838"></a>Forsyth CJ, Hernandez S, Olmedo W, et al. Safety profile of nifurtimox for treatment of Chagas disease in the United States. <i>Clin Infect Dis</i>. 2016;63(8):1056-1062. doi: 10.1093/cid/ciw477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/27432838/pubmed" id="27432838" target="_blank">27432838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21628620">
<a name="21628620"></a>Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. <i>Mayo Clin Proc.</i> 2011;86(6):561-583.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/21628620/pubmed" id="21628620" target="_blank">21628620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34748572">
<a name="34748572"></a>Kuemmerle A, Schmid C, Bernhard S, et al. Effectiveness of nifurtimox eflornithine combination therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study. <i>PLoS Negl Trop Dis</i>. 2021;15(11):e0009903. doi:10.1371/journal.pntd.0009903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/34748572/pubmed" id="34748572" target="_blank">34748572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lampit.1">
<a name="Lampit.1"></a>Lampit (nifurtimox) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30220883">
<a name="30220883"></a>Meymandi S, Hernandez S, Park S, Sanchez DR, Forsyth C. Treatment of Chagas disease in the United States. <i>Curr Treat Options Infect Dis</i>. 2018;10(3):373-388. doi: 10.1007/s40506-018-0170-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/30220883/pubmed" id="30220883" target="_blank">30220883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31415566">
<a name="31415566"></a>Moroni S, Marson ME, Moscatelli G, et al. Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas disease. <i>PLoS Negl Trop Dis</i>. 2019;13(8):e0007647. doi: 10.1371/journal.pntd.0007647.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/31415566/pubmed" id="31415566" target="_blank">31415566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29340450">
<a name="29340450"></a>Olivera MJ, Fory JA, Olivera AJ. Therapeutic drug monitoring of benznidazole and nifurtimox: a systematic review and quality assessment of published clinical practice guidelines. <i>Rev Soc Bras Med Trop</i>. 2017;50(6):748-755. doi:10.1590/0037-8682-0399-2016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/29340450/pubmed" id="29340450" target="_blank">29340450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19559476">
<a name="19559476"></a>Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicenter, randomized, phase III, non-inferiority trial. <i>Lancet.</i> 2009;374(9683):56-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/19559476/pubmed" id="19559476" target="_blank">19559476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23209861">
<a name="23209861"></a>Schmid C, Kuemmerle A, Blum J, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. <i>PLoS Negl Trop Dis</i>. 2012;6(11):e1920. doi: 10.1371/journal.pntd.0001920.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/23209861/pubmed" id="23209861" target="_blank">23209861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 4, 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed August 19, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4630485">
<a name="4630485"></a>Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. <i>Arzneimittelforschung</i>. 1972;22(9):1624-1635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifurtimox-drug-information/abstract-text/4630485/pubmed" id="4630485" target="_blank">4630485</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). <i>WHO Model Prescribing Information: Drugs Used in Parasitic Diseases</i>. 2nd ed. Geneva, Switzerland: World Health Organization; 1995.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO)/Department of Control of Neglected Tropical Diseases. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. Geneva, Switzerland: World Health Organization; 2019. https://www.who.int/trypanosomiasis_african/resources/9789241550567/en. Accessed October 29, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 126252 Version 50.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
